Free Trial

Kura Oncology (KURA) Competitors

Kura Oncology logo
$6.24 +0.04 (+0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$6.45 +0.21 (+3.37%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KURA vs. AAPG, KYMR, BHVN, IBRX, HRMY, TWST, BLTE, KNSA, ARWR, and CGON

Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Biohaven (BHVN), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Arrowhead Pharmaceuticals (ARWR), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

Kura Oncology vs.

Kura Oncology (NASDAQ:KURA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Kura Oncology presently has a consensus target price of $24.50, indicating a potential upside of 293.01%. Given Kura Oncology's higher possible upside, equities analysts clearly believe Kura Oncology is more favorable than Ascentage Pharma Group International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.93
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kura Oncology received 439 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 69.73% of users gave Kura Oncology an outperform vote.

CompanyUnderperformOutperform
Kura OncologyOutperform Votes
440
69.73%
Underperform Votes
191
30.27%
Ascentage Pharma Group InternationalOutperform Votes
1
100.00%
Underperform Votes
No Votes

Ascentage Pharma Group International has higher revenue and earnings than Kura Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura Oncology$67.99M7.94-$152.63M-$2.10-2.97
Ascentage Pharma Group International$980.65M2.26N/AN/AN/A

In the previous week, Kura Oncology had 18 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 18 mentions for Kura Oncology and 0 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.16 beat Kura Oncology's score of 0.53 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Overall Sentiment
Kura Oncology Positive
Ascentage Pharma Group International Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Kura Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Kura OncologyN/A -44.09% -39.57%
Ascentage Pharma Group International N/A N/A N/A

Summary

Kura Oncology and Ascentage Pharma Group International tied by winning 6 of the 12 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KURA vs. The Competition

MetricKura OncologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$537.98M$6.47B$5.32B$8.44B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.639.0726.8119.78
Price / Sales7.94255.02387.95118.50
Price / CashN/A65.8538.2534.62
Price / Book1.176.436.774.52
Net Income-$152.63M$143.98M$3.23B$248.32M
7 Day Performance4.77%2.34%1.73%0.58%
1 Month Performance-1.20%4.47%10.92%13.09%
1 Year Performance-72.35%-2.70%17.16%7.74%

Kura Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KURA
Kura Oncology
4.3095 of 5 stars
$6.24
+0.6%
$24.50
+292.6%
-72.0%$540.23M$67.99M-2.64130Analyst Forecast
Analyst Revision
AAPG
Ascentage Pharma Group International
N/A$24.20
-0.5%
N/AN/A$2.11B$980.65M0.00600News Coverage
Positive News
Gap Down
KYMR
Kymera Therapeutics
2.7461 of 5 stars
$32.17
+7.0%
$55.53
+72.6%
-14.7%$2.09B$47.07M-13.75170Positive News
Analyst Forecast
BHVN
Biohaven
3.46 of 5 stars
$20.47
+1.1%
$62.54
+205.5%
-59.4%$2.09BN/A-2.19239Analyst Downgrade
IBRX
ImmunityBio
1.8449 of 5 stars
$2.36
+14.0%
$12.19
+416.4%
-61.1%$2.08B$14.75M-2.57590Analyst Upgrade
High Trading Volume
HRMY
Harmony Biosciences
4.7828 of 5 stars
$35.65
+4.7%
$52.33
+46.8%
+16.4%$2.05B$744.85M16.90200Positive News
TWST
Twist Bioscience
4.2833 of 5 stars
$32.95
+6.9%
$50.40
+53.0%
-35.4%$1.97B$347.68M-9.75990Positive News
BLTE
Belite Bio
2.0509 of 5 stars
$61.99
+1.5%
$96.67
+55.9%
+48.2%$1.97BN/A-55.8510News Coverage
Analyst Downgrade
Analyst Revision
KNSA
Kiniksa Pharmaceuticals
2.9152 of 5 stars
$26.84
+3.1%
$38.80
+44.6%
+34.8%$1.95B$481.17M-191.70220Insider Trade
ARWR
Arrowhead Pharmaceuticals
3.517 of 5 stars
$13.97
+7.2%
$41.44
+196.7%
-38.8%$1.92B$2.50M-2.70400News Coverage
Analyst Forecast
Analyst Revision
CGON
CG Oncology
2.2204 of 5 stars
$25.16
+6.0%
$57.70
+129.3%
-9.5%$1.92B$1.14M-17.7261Analyst Forecast

Related Companies and Tools


This page (NASDAQ:KURA) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners